Coxiella burnetii pathogen, which causes Q fever, is one of the most dangerous pathogens transmitted from the livestock to humans. The only immunization against this disease is the Q-Vax® vaccine, which is used in Australia, as it is not authorized by other countries due to its adverse side effects. Today, growing attention is being paid to the safety of subunit vaccines. Therefore, performing in silico pre-empirical studies on the functionality of recombinant proteins will be more cost-effective than empirical experiments. In this study, P1 and YbgF antigens of C. burnetii were examined and their epitopes were identified. In this case, the most accurate online tools were employed to predict the B cell, T cell and IFN-γ epitopes. Then, the best epitopes were selected based on their antigenicity potency and resistance to digestive compounds. High-ranked epitopes and Heparin-Binding Hemagglutinin as an adjuvant were used to engineer a poly-epitope fusion protein vaccine. Then, physicochemical features, secondary and tertiary structures of the engineered vaccine were evaluated. Finally, the molecular docking of the engineered vaccine and TLR4/MD2 was done. The results of the different analysis revealed that the engineered vaccine can be potentially considered as a potent candidate for fighting with C. burnetii.